(403) 770-2469 info@marvelbiotechnology.com
Marvel Biosciences
  • About Us
  • Technology
    • MB-204
    • Non-Hallucinogenic Neuroplasticity Program
  • News
  • Investors
  • Contact Us
Select Page

Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204

Mar 18, 2026 | News

Calgary, Alberta – March 18, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum...

Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders

Feb 18, 2026 | News

Calgary, Alberta – Wednesday, February 18, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), is pleased to announce that it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC...
Next Entries »
  • Twitter
Copyright 2022 Marvel Biosciences Corp. All rights reserved.